An observational study in Inflammatory Bowel Diseases, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-04.
Sponsored by Assiut University · Observational
Inflammatory bowel diseases (IBD), encompassing ulcerative colitis (UC) and Crohn's disease (CD), are chronic, relapsing inflammatory disorders of the gastrointestinal tract with significant morbidity and impact on patients' quality of life. Despite advances in diagnostic and therapeutic strategies, many patients continue to experience complications, frequent hospitalizations, and impaired long-term outcomes. Identifying prognostic factors that can predict disease course and response to therapy is therefore crucial in guiding clinical management and optimizing resource utilization.
Anemia is one of the most frequent extraintestinal manifestations of IBD, with prevalence estimates ranging from 20% to 70% depending on disease activity and population studied. The pathogenesis of anemia in IBD is multifactorial, including iron deficiency due to chronic intestinal blood loss, anemia of chronic disease driven by inflammation, vitamin B12 or folate deficiency, and medication-related bone marrow suppression. Anemia has been consistently associated with increased disease activity, reduced health-related quality of life, higher rates of hospitalization, and poorer overall prognosis in IBD patients.
Given its potential as a simple and accessible biomarker, hemoglobin level and anemia status may serve as valuable predictors of disease outcome. However, local data from Egyptian populations, particularly from Assiut University Hospitals, remain scarce. Studying anemia as a prognostic factor in IBD patients may provide insight into disease severity, help stratify patients at higher risk, and support the development of tailored therapeutic and monitoring strategies. This research aims to fill this knowledge gap by evaluating the prognostic significance of anemia in IBD patients managed at Assiut University Hospitals.
1,460 studies on the registry are indexed under Inflammatory Bowel Diseases; 437 are open to participants now.
This study's planned enrollment of 83 is below the median of 139 across 645 observational studies indexed under Inflammatory Bowel Diseases.
Browse Inflammatory Bowel Diseases studies →Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adult patients (≥18 years old) diagnosed with inflammatory bowel diseases (ulcerative colitis or Crohn's disease).
Adult patients (≥18 years old) diagnosed with inflammatory bowel diseases (ulcerative colitis or Crohn's disease).
Exclusion Criteria:
Patients with other chronic hematological disorders unrelated to IBD (e.g., aplastic anemia, hemoglobinopathies).
Adult patients (≥18 years old) diagnosed with inflammatory bowel diseases (ulcerative colitis or Crohn's disease).
hospitalization rate
Time frame: baseline
No study locations are listed for this record.
This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University